257 related articles for article (PubMed ID: 16263207)
1. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
Mulhall JP; Montorsi F
Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
[TBL] [Abstract][Full Text] [Related]
2. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Berner MM; Kriston L; Harms A
Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
[TBL] [Abstract][Full Text] [Related]
4. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Vickers MA; Satyanarayana R
Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
[TBL] [Abstract][Full Text] [Related]
6. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
7. Emerging oral drugs for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
[TBL] [Abstract][Full Text] [Related]
8. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
Kim NN
Int J Impot Res; 2003 Oct; 15 Suppl 5():S13-9. PubMed ID: 14551572
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
13. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Bella AJ; Brant WO; Lue TF; Brock GB
Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
15. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
Lee J; Pommerville P; Brock G; Gagnon R; Mehta P; Krisdaphongs M; Chan M; Chan J; Dickson R
BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
[TBL] [Abstract][Full Text] [Related]
16. Patients' preference in the treatment of erectile dysfunction: a critical review of the literature.
Morales AM; Casillas M; Turbi C
Int J Impot Res; 2011; 23(1):1-8. PubMed ID: 21191396
[TBL] [Abstract][Full Text] [Related]
17. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
18. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
Mehrotra N; Gupta M; Kovar A; Meibohm B
Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]